Jesús G Lugo
220 posts

Jesús G Lugo
@LugoMd
Assistant Professor, Hematologist at @KUCancercenter specializing in #Leukemia and #MDS . Former Chief Hematology/Oncology Fellow @EinsteinMed @MontefioreNYC
Kansas City, KS Katılım Haziran 2020
210 Takip Edilen268 Takipçiler

First ever ASH oral abstract in the books. Really a dream, I remember my first ash and how far and impossible it looked. Just thankful of everyone who has helped me along the way.
#ASH25

English
Jesús G Lugo retweetledi

#ASH25 attendees: Head over to the Valencia Room (W415A) from 2-3:30 pm where lead author Jesus Gonzalez-Lugo is discussing for “Characteristics and clinical outcomes of patients (pts) with Acute Myeloid Leukemia (AML) with Mecom rearrangements: An analysis from the MARROW consortium.” #KUBloodCancer #AML

English
Jesús G Lugo retweetledi

Happy #ASH2025 week! The🩸MARROW consortium is publishing on #AML. Honored to have been part of the inaugural publication in @BrJHaem ! doi.org/10.1111/bjh.70…
🔑Oral Abstract Session Sat, 12/6 (245-330P)👇
🧬11q23/KMT2A-r AML
🧬MECOM-r AML
📚Great work & great group! #leusm



English
Jesús G Lugo retweetledi

A great way to start ASH week! Our Real World Analysis of CPX-351 in younger & older AML-MR pts now in-print @BrJHaem. Kudos to @DPetersMD who led this analysis from the Marrow Consortium @AkEisfeld @madanatyazan @BKRagonMD @LancetJeff @UNC_Lineberger
onlinelibrary.wiley.com/doi/10.1111/bj…
English
Jesús G Lugo retweetledi

Presentation @EHA_Hematology #EHA25 & publication of our Phase 1b Aza+Ven+Revumenib study led by @LeukDocJZ by the Beat AML Consortium by @LLSusa 👇🏾


Journal of Clinical Oncology@JCO_ASCO
‼️ #EHA2025 #JCO simultaneous publication by @LeukDocJZ et al: Azacitidine, Venetoclax and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia: brnw.ch/21wTlXR
English
Jesús G Lugo retweetledi

Several @KUcancercenter experts contributed to the recently published @ASCO Educational Book article "Moving Away From Standard Induction in Newly Diagnosed Acute Myeloid Leukemia" ➔ ascopubs.org/doi/10.1200/ED…
#CancerResearch #ClinicalTrials #ASCO25 #AML #KUBloodCancer
English
Jesús G Lugo retweetledi

Beautiful day in #Rotterdam @Visit_NL for the MDS Foundation Meeting #2025 — honored to be here in this stunning city. Great opening by @garciamanero on #HR-MDS and an exciting agenda ahead. Looking forward to an inspiring few days! #MDS25 @MDSFoundation @utswcancer


English
Jesús G Lugo retweetledi

🔥 Excited for our Phase 1 study Ven + 7+3 for Newly Diagnosed AML
demonstrating 85% CR (86% MRD-neg)
@BloodJournal @ MontefioreNYC @EinsteinMed @MontefioreNYC
Eric J. Feldman @MendelGoldfing2
@mkonople @Amitvermamds @aditishasMD @Gritsman_lab
#leusm
doi.org/10.1182/blood.…
English
Jesús G Lugo retweetledi

Honored to present the James D. Cook, M.D. Memorial Lecture on MDS at the @KansasUniv #ASH24 Review. Grateful for the invitation and Dr. @AYACOUB7's inspiring opening remarks. Let the learning begin! 🎊🎊 @UTSWMedCenter @utswcancer




English
Jesús G Lugo retweetledi

#myeloMATCH MM1YA-S01 is enrolling adults ages 18-59 with newly diagnosed high-risk #AML.
Randomized 5-arm comparison of induction therapies. Primary endpoint: MRD-negative complete remission rate. SWOG.org/clinical-trial…
Co-PI: Tara Lin, MD @KUcancercenter #leusm #AMLsm

English
Jesús G Lugo retweetledi

The success of blinatumomab in first line ALL continues.
The next step is working for global access and equity! Humans with leukemia should not die just because of where they were born.
Read ASH NEWS out now: tinyurl.com/yz8cpxh6 #ASH24

English

Great and varied session about menin inhibitors, bleximenib 33% CRc in R/R MLL and NPM1mut #AMLsm Enzomenib CRc 48% MLL, 47% NPM1, no dose reduction for azoles, 7+3/Zifto 100% CRc! In NPM1 #ASH24 @LeukDocJZ @DrEmmaSearle @Dr_AmerZeidan



English

Jesús G Lugo retweetledi

AML genomic data pooling between 🇺🇸MARROW consortium 🤝 🇲🇽GTLA led by @LugoMd to clarify the meaning of “hispanic” #ASH24.
Mexicans working together in both sides of the Rio Bravo (Grande)
@NidiaZa07175883 #Leusm

English

Great presentation @YannisMantz @EinsteinDeptMed presenting on 7+3 and Venetoclax in #AMLsm with CR rates of 80% with 85% MRD negativity #ASH24



English

First thing I did getting to #ASH24 in San Diego? Getting Tacos 🌮 🌮 in Tacos el gordo, the best!


English
Jesús G Lugo retweetledi

Next up, @j_snyder0132 presenting #ASH24 poster 2411 on teclistamab in BCMA therapy exposed vs naive in RRMM!
@KUcancercenter @thisisJamesD @Abdallah81MD @NausheenAhmedMD @mumairmushtaq
#oncopharm

English
Jesús G Lugo retweetledi

So proud of @DPetersMD @UNC_Lineberger for a stellar presentation at #ASH24 on outcomes of CPX in younger AML pts w/ MDS mutations. Younger pts w/ AML & MDS mu had better outcomes w/ CPX despite equivalent alloBMT rates. @AkEisfeld @madanatyazan @mjhochman



English

@mmejia91 @jaimegzz353 Que nos pongan un stand en ASH con tacos estaría bien.
Español

@LugoMd @jaimegzz353 A este paso te van a dar el 10% de las ventas por la promoción que les haces
Español

@jaimegzz353 Cómo se llaman los tacos donde hay caramelos? Que está bien buenos!!
Español




